Status and phase
Conditions
Treatments
About
The primary purpose of this study is to determine whether the investigational drug XmAb541 is safe and well tolerated, and to determine an optimal and safe dose(s) for further study. The study will also evaluate effect of XmAb541 on tumor outcomes.
Enrollment
Sex
Ages
Volunteers
Inclusion and exclusion criteria
Key Inclusion Criteria:
Key Exclusion Criteria:
Primary purpose
Allocation
Interventional model
Masking
212 participants in 1 patient group
Loading...
Central trial contact
Chet Bohac, Pharm D, MD, MSc
Data sourced from clinicaltrials.gov
Clinical trials
Research sites
Resources
Legal